Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to ...

GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...

Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary ...

In the trial, Novo Nordisk said, the “vast majority” of side effects of oral semaglutide were “mild to moderate and diminished over time.” All GLP-1 medications are associated with side ...

The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

Wegovy is part of a class of drugs called GLP-1 receptor agonists, and its active ingredient, semaglutide, is also approved to treat type 2 diabetes as Ozempic. Novo Nordisk’s trial was limited ...